CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Risperidonecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04418466
NCT04418466Phase 2Completed
CompareCT.gov

Open-Label Study in Stable Schizophrenia Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant (DLP-114)

Delpor, Inc.·interventional·Posted Jun 5, 2020·Updated Dec 27, 2024

In Brief

A Phase 2 clinical trial evaluating Risperidone for Schizophrenia. Completed, enrolled 34 participants across 2 sites.

Detailed Summary

This is an Open-Label Study in Stable Schizophrenia Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJun 5, 2020
Enrollment StartApr 1, 2021
Primary CompletionFeb 10, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.1 years ago

Interventions

Risperidonecombination

Risperidone Implant